Schrodinger, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Omeros (OMER) +13%, Alpha Teknova (TKNO) +5%, BioLife (BLFS) +6%, Schrodinger (SDGR) +4%, and InfuSystem (INFU) +2% hit 52-week highs. OMER reported $32.2M Q2 sales for YARTEMIS. TKNO launched Fill-Tek, with Q2 revenue up 18%. BLFS to be acquired by Repligen (RGEN) for $1.5B, Q2 revenue up 21%. SDGR co-founded Tectora. INFU Q2 revenue $36.9M, up 2.6%.
Akinsanya Karen (See Remarks) sold 31,599 shares of Schrodinger, Inc. (SDGR) at an average of $29.37 ($28.00–$30.00, $0.93M total) across 2 trades on 2026-09-17 under a Rule 10b5-1 trading plan.
Schrödinger Inc. (SDGR) options flow shows bullish positioning, with significant call buying ahead of potential catalysts. The stock is down 3.64% intraday at $29.14 but up 52.79% in a week and 84.39% in 3 months. Notable options include Sept 18 $30 calls expiring today and new positions in Oct and Dec calls, indicating bullish sentiment. Volatility remains high, with 3-month implied volatility at 83.32%. The recent rally follows a Novartis partnership and $700M R&D collaboration. Investors are
Over the past 7 days, AlphAI's AI scored 1 news story mentioning SDGR (Schrodinger, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent SDGR coverage spans market movers, corporate actions and insider activity.
In the last 30 days, SDGR insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($928K). The most active reporter was Akinsanya Karen, See Remarks, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Funding news supports near‑term bullish sentiment.
The insider sale indicates potential downside pressure as an executive is reducing ownership.
Increased call volume and elevated implied volatility suggest upside pressure, but high premiums increase risk if catalyst fails.
The sharp price rally may attract short-covering and momentum traders, but mixed fundamentals could limit upside.
Regulatory filing indicates compliance, not a growth catalyst.
AlphAI scores every news story that mentions SDGR with an AI model for sentiment and relevance, and aggregates insider trades from Schrodinger, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Omeros (OMER) +13%, Alpha Teknova (TKNO) +5%, BioLife (BLFS) +6%, Schrodinger (SDGR) +4%, and InfuSystem (INFU) +2% hit 52-week highs. OMER reported $32.2M Q2 sales for YARTEMIS. TKNO launched Fill-Tek, with Q2 revenue up 18%. BLFS to be acquired by Repligen (RGEN) for $1.5B, Q2 revenue up 21%. SDGR co-founded Tectora. INFU Q2 revenue $36.9M, up 2.6%.
2 min readAkinsanya Karen (See Remarks) sold 31,599 shares of Schrodinger, Inc. (SDGR) at an average of $29.37 ($28.00–$30.00, $0.93M total) across 2 trades on 2026-09-17 under a Rule 10b5-1 trading plan.
1 min readSchrödinger Inc. (SDGR) options flow shows bullish positioning, with significant call buying ahead of potential catalysts. The stock is down 3.64% intraday at $29.14 but up 52.79% in a week and 84.39% in 3 months. Notable options include Sept 18 $30 calls expiring today and new positions in Oct and Dec calls, indicating bullish sentiment. Volatility remains high, with 3-month implied volatility at 83.32%. The recent rally follows a Novartis partnership and $700M R&D collaboration. Investors are
2 min readSchrödinger (SDGR) stock surged 60% this week, crossing $30. The rally faces resistance near $37. Software metrics show slowing growth, with ACV up 4% to $198.5M in 2025. Drug pipeline faces uncertainty, with key programs seeking partners. Cash and securities increased to $418.8M by Q2 2026. Investors watch for execution risks.
2 min readVicor Corp (VICR) shares rose 13.5% to $208.73 after granting a license for its patents. Other stocks gaining include Securitize (SECZ) +21%, Generac (GNRC) +19.6%, and Arm (ARM) +6.7%. Generac's rise follows a supply deal with Amazon and a price target increase. Micron (MU) gained 5.6% amid a memory stock rally.
2 min readSchrödinger (SDGR) licensed two immunology programs to Tectora, a new biotech it co-founded. Tectora raised $55m in Series A funding. SDGR gets equity, milestones, and royalties. Tectora will advance the programs toward clinical trials, using SDGR's computational platform. SDGR has similar partnerships with Ajax, Nimbus, and Structure Therapeutics, generating $750m in proceeds.
2 min readSchrodinger Inc (NASDAQ: SDGR) launched Tectora, a biotech firm focused on immunology and inflammation, backed by a $55M Series A funding. SDGR's P/S ratio is 7.7x, below its 10.3x historical median, suggesting cautious growth expectations. Its GF Score™ is 72/100, indicating moderate fundamental strength with notable valuation and momentum but weak profitability. Insider activity shows $1.4M in selling over the past year, while institutional sentiment is mixed.
2 min readSchrodinger has launched Tectora Therapeutics, a new company, in partnership with RA Capital and New Enterprise Associates. The move is part of Schrodinger's strategy to expand its drug discovery platform. The company's stock has seen a 5-day change of -4.14% and a year-to-date change of -8.05%.
1 min readSchrödinger co-founded Tectora Therapeutics, a biotech company focused on immunology and inflammation treatments. Schrödinger contributed two drug programs and received equity, milestones, and royalties. Tectora raised $55 million in Series A funding. Schrödinger will leverage its computational platform to advance the programs.
4 min readBiopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.
7 min read
